Page 236 - 2021_05-Haematologica-web

H. El Hajj et al.
Clinical outcomes of a novel therapeutic
vaccine with Tax peptide-pulsed dendritic cells for adult T cell leukaemia/lymphoma in a pilot study. Br J Haematol. 2015; 169(3):356-367.
13. Bazarbachi A, Plumelle Y, Carlos Ramos J, et al. Meta-analysis on the use of zidovu- dine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol. 2010;28(27):4177-4183.
14. Bazarbachi A, Suarez F, Fields P, et al. How I treat adult T-cell leukemia/lymphoma. Blood. 2011;118(7):1736-1745.
15. Gill PS, Harrington W, Kaplan MH, et al. Treatment of adult T-cell leukemia-lym- phoma with a combination of interferon alfa and zidovudine. N Engl J Med. 1995;332(26):1744-1748.
16. Hermine O, Bouscary D, Gessain A, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med. 1995; 332(26):1749-1751.
17. Malpica L, Pimentel A, Reis IM, et al. Epidemiology, clinical features, and out- come of HTLV-1-related ATLL in an area of prevalence in the United States. Blood Adv. 2018;2(6):607-620.
18. Bazarbachi A, El-Sabban ME, Nasr R, et al. Arsenic trioxide and interferon-alpha syn- ergize to induce cell cycle arrest and apop- tosis in human T-cell lymphotropic virus type I-transformed cells. Blood. 1999; 93(1):278-283.
19. Mahieux R, Pise-Masison C, Gessain A, et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-depen- dent mechanism involving Bcl-2 cleavage. Blood. 2001;98(13):3762-3769.
20. Kchour G, Tarhini M, Kooshyar MM, et al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, inter- feron alpha, and zidovudine in newly diag- nosed chronic adult T-cell leukemia/lym- phoma (ATL). Blood. 2009;113(26):6528- 6532.
21. El Hajj H, El-Sabban M, Hasegawa H, et al. Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemia. J Exp Med. 2010;207(13): 2785-2792.
22.Marcais A, Cook L, Witkover A, et al. Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia/lym- phoma. Retrovirology. 2020;17(1):5.
23. Kagdi H, Demontis MA, Ramos JC, et al. Switching and loss of cellular cytokine pro- ducing capacity characterize in vivo viral infection and malignant transformation in human T- lymphotropic virus type 1 infec- tion. PLoS Pathog. 2018;14(2):e1006861.
24.Kchour G, Rezaee R, Farid R, et al. The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocom- petent-like" cytokine expression profile in patients with adult T-cell leukemia lym- phoma. Retrovirology. 2013;10:91.
25. Sawada L, Nagano Y, Hasegawa A, et al. IL- 10-mediated signals act as a switch for lym- phoproliferation in human T-cell leukemia virus type-1 infection by activating the STAT3 and IRF4 pathways. PLoS Pathog. 2017;13(9):e1006597.
26.Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002; 100(9):3175-3182.
27. Weisser SB, van Rooijen N, Sly LM. Depletion and reconstitution of macrophages
in mice. J Vis Exp. 2012; (66):4105.
28. El-Sabban ME, Nasr R, Dbaibo G, et al. Arsenic-interferon-alpha-triggered apopto- sis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-κB B activation. Blood. 2000; 96(8):
2849-2855.
29. Camacho V, McClearn V, Patel S, et al.
Regulation of normal and leukemic stem cells through cytokine signaling and the microenvironment. Int J Hematol. 2017; 105(5):566-577.
30. Gun SY, Lee SWL, Sieow JL, et al. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174.
31. Couper KN, Blount DG, Riley EM. IL-10: the master regulator of immunity to infec- tion. J Immunol. 2008;180(9):5771-5777.
32. Wong RWJ, Tan TK, Amanda S, et al. Feed- forward regulatory loop driven by IRF4 and NF-κB in adult T-cell leukemia/lymphoma. Blood. 2020;135(12):934-947.
33. Higuchi Y, Yasunaga JI, Mitagami Y, et al. HTLV-1 induces T cell malignancy and inflammation by viral antisense factor- mediated modulation of the cytokine sig- naling. Proc Natl Acad Sci U S A. 2020; 117(24):13740-13749.
34. Weinstein IB. Cancer. Addiction to onco- genes: the Achilles heal of cancer. Science. 2002;297(5578):63-64.
35. Ablain J, Rice K, Soilihi H, et al. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure. Nat Med. 2014;20(2):167- 174.
36.Nasr R, Guillemin MC, Ferhi O, et al. Eradication of acute promyelocytic leukemia-initiating cells through PML- RARA degradation. Nat Med. 2008; 14(12):1333-1342.
1456
haematologica | 2021; 106(5)